Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers | Memorial Sloan Kettering Cancer Center

Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers | Memorial Sloan Kettering Cancer Center

Genomic Markers Can Predict the Presence of Lynch Syndrome across a Broad Spectrum of Cancers

• Share
• Print

Chicago, IL, 

Saturday, June 2, 2018

Zsofia Stadler, MD, clinic director of the Clinical Genetics Service and a medical oncologist

Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.